New research suggests that adopting a low-fat vegan diet is significantly cheaper than both a standard American diet and a Mediterranean diet . Read more: Mediterranean Diet Vs Plant-Based: Which Is Best? The research was conducted by the Physicians Committee For Responsible Medicine (PCRM) and published in the latest issue of the scientific journal Jama Network Open . PCRM carried out a secondary analysis of a 2019 randomized clinical trial. This analysis found that total food costs were 19 percent lower on a vegan diet than on a standard American diet (SAD) featuring animal products and refined ingredients. Furthermore, costs were 25 percent lower when compared to a Mediterranean diet. The savings were mostly associated with eschewing traditional meat, which offset the additional outgoings for vegetables and plant-based proteins. Overall, the analysis suggests that people following a SAD diet could save more than $650 per year by going vegan, while those following a Mediterranean diet could save over $870. Read more: National Dietary Guides Should Be Based On Healthy Plant-Based Diet, Says Study Vegan diets cheaper and more sustainable This latest analysis is preceded by PCRM research from 2023 that found low-fat vegan diets were around 16 percent less expensive than diets including meat, dairy, and egg. “As the cost of groceries remains stubbornly high, consumers should swap the meat and dairy products for a low-fat vegan diet based on fruits, vegetables, grains, and beans,” said Hana Kahleova, the lead author of the new paper and director of clinical research at PCRM, per Technology Networks . “A vegan diet won’t just save money; it could save lives by helping to avoid or improve conditions like obesity, type 2 diabetes, and heart disease.” A separate report by Bryant Research and Plant-Based Universities from October found that Universities could save half a million pounds and cut 84 percent of greenhouse gas emissions from food by switching to entirely plant-based catering. Plant-Based Universities campaigner Agnes Sales called such a move “common sense.” Read more: Plant-Based Milk And Meat Are Now Mainstream In Europe, Report FindsIn their final fixture of 2024, Kai Havertz scored the only goal of the game midway through the opening period. Arsenal’s victory takes them back to within six points of leaders Liverpool, having played one match more than the Reds, and a point clear of Chelsea following their Boxing Day defeat to Fulham. Ipswich, although much improved in the second half, have now lost five of their last six games, and remain just one place off the bottom of the table, three points away from safety. 🎯 pic.twitter.com/hDd5bkHwXr — Arsenal (@Arsenal) December 27, 2024 Mikel Arteta’s men have been rocked by Bukayo Saka’s hamstring injury which could keep the England winger, who has nine goals and 13 assists this season, out of action for the next two months. Gabriel Martinelli was handed the unenviable task of filling Saka’s shoes on Arsenal’s right-hand side and the Brazilian was involved in the only goal of the evening. The Ipswich defence failed to deal with Martinelli’s cross, with the ball falling to Leandro Trossard on the opposite side of the area. Trossard fought his way to the byline before fizzing his cross into the box for Havertz to convert from a matter of yards. It was Havertz’s third goal in four matches, his 12th of the season, and no less than the hosts, who at that stage of the match had enjoyed a staggering 91.4 per cent of the possession, deserved. Heading into Friday’s fixture, Arsenal had lost only one of their last 75 Premier League games when they had opened the scoring, and their triumph here rarely looked in doubt following Havertz’s strike. Three points that take Arsenal into second 🪜 #ARSIPS pic.twitter.com/Dx3s6XlwQ2 — Premier League (@premierleague) December 27, 2024 Havertz thought he had doubled Arsenal’s lead with 34 minutes gone when he converted Gabriel Jesus’ cross. But Jesus – handed his third successive start for the first time in a year – strayed into an offside position in the build-up. When referee Darren England blew for half-time, Ipswich had failed to touch the ball in Arsenal’s box, becoming just the second side to do so in the Premier League this season. Nottingham Forest were the other, away at Liverpool, before they went on to inflict Arne Slot’s sole defeat of his tenure so far. And for all of Arsenal’s possession, while they held just a one-goal advantage, Ipswich knew they were still in the game. An encouraging start to the second half for the Tractor Boys ensued, albeit without testing David Raya in the Arsenal goal. Shortly after the hour mark, Gabriel should have settled any growing Emirates nerves when he arrived unmarked to Declan Rice’s corner, but the defender headed wide of Arijanet Muric’s post when it looked easier to score. Just over an hour on the clock. #ARSIPS pic.twitter.com/JXNipX1J1Z — IPSWICH TOWN (@IpswichTown) December 27, 2024 Martin Odegaard then forced a fine fingertip save from Muric at his near post after a mazy run and shot from the Arsenal skipper. Rice’s stinging goal-bound volley from the following corner was blocked by Dara O’Shea as Arsenal pushed for a game-killing second. Havertz should have tapped home Trossard’s header but he fluffed his lines. And moments later, substitute Mikel Merino’s effort was diverted from danger by a diving Muric. Ipswich looked to catch Arsenal on the counter, but the match ended without them registering a single effort on Raya’s goal. Ipswich fans goaded their opponents with chants of “boring, boring Arsenal”, but it was the Gunners who enjoyed the last laugh as they saw out 2024 with a win which keeps the pressure on Liverpool.
Schoolgirl with hearing issue meets Tasha Ghouri in Thirsk
NoneKingsview Wealth Management LLC Takes $235,000 Position in Rocket Companies, Inc. (NYSE:RKT)
London honored for supporting student mental health and eliminating barriers to care NATICK, Mass. , Dec. 23, 2024 /PRNewswire/ -- The Boston Business Journal honored Uwill founder and CEO Michael London as part of its 2025 Innovators in Healthcare list . Honorees represent a cross-section of Boston -based innovators addressing some of the most urgent and pressing challenges in the health care industry. London is the founding CEO of Uwill , the leading mental health and wellness solution proudly supporting more than 3 million students at 400 institutions globally. Utilizing its proprietary technology and counselor team, Uwill pioneered the first student and therapist matching platform. The solution offers an immediate appointment with a licensed counselor based on student preferences, all modalities of teletherapy, a direct crisis connection, wellness programming, realtime data, and support. "It's truly an honor to be recognized among this incredible group of innovators," said Michael London , Uwill founder and CEO. "At Uwill, our mission is to break down barriers to mental health care, delivering immediate and accessible support to students worldwide. This recognition reflects more than innovation—it underscores our unwavering commitment to addressing a vital need for students everywhere." London is a recognized thought-leader and pioneer within social impact entrepreneurship, having created more than one billion dollars in company value throughout his career. In 2013, he founded Examity, a leader in learning validation and online proctoring. Prior, London led Bloomberg Institute, an EdTech start-up funded by former New York City Mayor Michael Bloomberg . Earlier in his career, he founded College Coach and co-founded EdAssist, both acquired by Bright Horizons Family Solutions. In 2019, he was a finalist for the EY Entrepreneur of the Year Award and held a position on the Massachusetts Governor's Commission for Digital Education and Lifelong Learning. Michael is a current Trustee at Beth Israel Deaconess Medical Center. He is a Member of the Advisory Board at Babson College where he graduated with honors. He also received his MBA from Boston University . About Uwill: Uwill is the leading mental health and wellness solution for colleges and students. As the most cost-effective way to enhance a college's mental health offering, Uwill partners with more than 400 institutions, including Princeton University , the Ohio State University , Santa Fe Community College , and University of Alabama - Online. Uwill is also the exclusive teletherapy education partner for the Online Learning Consortium and teletherapy education partner of NASPA. For more information, visit uwill.com . Contact: Brett Silk bsilk@uwill.com View original content to download multimedia: https://www.prnewswire.com/news-releases/uwill-founder--ceo-michael-london-named-innovator-in-healthcare-302338655.html SOURCE Uwill, Inc'B***h new laws!' California shoplifting suspect surprised stealing is now a felonyLondon honored for supporting student mental health and eliminating barriers to care NATICK, Mass. , Dec. 23, 2024 /PRNewswire/ -- The Boston Business Journal honored Uwill founder and CEO Michael London as part of its 2025 Innovators in Healthcare list . Honorees represent a cross-section of Boston -based innovators addressing some of the most urgent and pressing challenges in the health care industry. London is the founding CEO of Uwill , the leading mental health and wellness solution proudly supporting more than 3 million students at 400 institutions globally. Utilizing its proprietary technology and counselor team, Uwill pioneered the first student and therapist matching platform. The solution offers an immediate appointment with a licensed counselor based on student preferences, all modalities of teletherapy, a direct crisis connection, wellness programming, realtime data, and support. "It's truly an honor to be recognized among this incredible group of innovators," said Michael London , Uwill founder and CEO. "At Uwill, our mission is to break down barriers to mental health care, delivering immediate and accessible support to students worldwide. This recognition reflects more than innovation—it underscores our unwavering commitment to addressing a vital need for students everywhere." London is a recognized thought-leader and pioneer within social impact entrepreneurship, having created more than one billion dollars in company value throughout his career. In 2013, he founded Examity, a leader in learning validation and online proctoring. Prior, London led Bloomberg Institute, an EdTech start-up funded by former New York City Mayor Michael Bloomberg . Earlier in his career, he founded College Coach and co-founded EdAssist, both acquired by Bright Horizons Family Solutions. In 2019, he was a finalist for the EY Entrepreneur of the Year Award and held a position on the Massachusetts Governor's Commission for Digital Education and Lifelong Learning. Michael is a current Trustee at Beth Israel Deaconess Medical Center. He is a Member of the Advisory Board at Babson College where he graduated with honors. He also received his MBA from Boston University . About Uwill: Uwill is the leading mental health and wellness solution for colleges and students. As the most cost-effective way to enhance a college's mental health offering, Uwill partners with more than 400 institutions, including Princeton University , the Ohio State University , Santa Fe Community College , and University of Alabama - Online. Uwill is also the exclusive teletherapy education partner for the Online Learning Consortium and teletherapy education partner of NASPA. For more information, visit uwill.com . Contact: Brett Silk bsilk@uwill.com View original content to download multimedia: https://www.prnewswire.com/news-releases/uwill-founder--ceo-michael-london-named-innovator-in-healthcare-302338655.html SOURCE Uwill, Inc
By Jason Gale | Bloomberg As COVID swept across California in early 2020, pediatric infectious diseases physician Karin Nielsen grew alarmed by the crisis erupting in maternity wards. Pregnant women were placed on life support, undergoing emergency C-sections as the virus triggered severe complications. Some died. Nielsen had just finished a research project on how the emerging infectious disease Zika was causing severe birth defects. Concerned the new coronavirus might have a similar impact, she began recruiting expectant mothers who tested positive for a new study. Soon after the study’s participants began giving birth, Nielsen’s colleagues at UCLA’s Mattel Children’s Hospital noticed an unusual number of their newborns requiring intensive care. Nielsen recalls another doctor stopping her to ask, “What’s wrong with the babies in your study?” NEXT PANDEMIC? How America lost control of the bird flu Sure enough, when researchers analyzed videos of the children lying on their backs in what’s called the General Movement Assessment, 14% of the infants showed signs of developmental problems. The test evaluates early motor functions and is often used to assess the risk of neurodevelopmental disorders including cerebral palsy. Later, during in-clinic assessments, the findings proved equally troubling. At 6-8 months old, 13 of 109 infants born to infected mothers — almost 12% — had failed to reach developmental milestones. In stark contrast, all infants in a control group born before the pandemic showed normal development. As additional participants from LA and Rio were enrolled, more unsettling results emerged. Around 11.6% of toddlers born to mothers with lab-confirmed SARS-CoV-2 infection during pregnancy showed cognitive, motor, or language problems indicative of neurodevelopmental delays. By comparison, only two of 128 unexposed controls — 1.6% — showed such issues. When the eldest of the Covid-exposed babies reached 28 months, the study found another concerning pattern: 23 of 211 children — almost 11% — screened positive for autism spectrum disorder. The finding, presented in May at a medical conference in Copenhagen, compared with an expected prevalence of 1-2% at that age, when some children begin showing signs of the condition. Around one in 36 or under 3% of children are eventually diagnosed with autism, according to the Centers for Disease Control and Prevention. “There’s something really going on,” Nielsen says. “We don’t want to alarm the world, but that’s what our data are showing.” The later findings, currently undergoing peer review ahead of publication, are a reminder that Covid’s long-term consequences, including higher risks for dementia and heart disease, continue to unravel almost five years after the pandemic began. While the virus is generally known to cause more severe symptoms in adults than in children, emerging research suggests that babies exposed to Covid in utero face elevated risks for preterm birth, congenital heart abnormalities and rare conditions, such as organs developing on the opposite side of the body. Greater odds of autism from in utero exposure to Covid would add another piece to the puzzle. The connection between the virus and autism remains inconclusive: some studies align with Nielsen’s findings, while others report little to no increased risk of developmental or behavioral issues. A limitation of Nielsen’s study is its relatively small sample size, with fewer than 250 mother-baby pairs. A robust understanding of the virus’ impact would likely require research involving more than 10,000 children, says Andrea Edlow, a maternal-fetal medicine specialist at Boston’s Massachusetts General Hospital. Such large-scale research has been difficult, particularly during the most deadly waves of the pandemic when clinic restrictions and medical emergencies obstructed consistent testing. Nielsen herself is wary of raising unnecessary fears. Autism remains something of a mystery, with its exact triggers still unclear. Scientists suspect an intersection of genetic and environmental factors, but the condition comes in many forms: some children have intellectual disabilities, while others don’t but still struggle with significant behavioral problems, complicating diagnoses. Many individuals with autism also experience co-occurring health issues such as attention-deficit/hyperactivity disorder, seizures, or chronic gastrointestinal problems. In much of the world, an awareness of autism is only starting to catch on. Global autism prevalence was estimated at 1 in 127 as of 2021 in a study published last week, more than double the 1-in-271 ratio reported in 2019, and researchers say this is likely driven by increased awareness and better diagnostic practices. The lack of clear explanations has provided fertile ground for myths, including the debunked belief that vaccines cause autism.Still, scientists say Nielsen’s study warrants serious attention due to the consistency of its findings. It also stands out for its rigor: trained physicians used standardized assessment tools at multiple points in time to evaluate developmental progress rather than relying on electronic health records or parent-completed questionnaires. Children born during the Covid era are now reaching the average age for autism diagnoses. Identifying developmental issues early can open the door to speech and behavioral therapies, which are proven to support a child’s development. This makes it a critical moment to study the pandemic’s impact. Nielsen, born to a Danish father and Brazilian mother in Rio de Janeiro, where she attended medical school, has dedicated much of her career to studying how maternal infections, such as HIV and Zika, affect child health. The mosquito-borne Zika virus is known for causing cerebral palsy and microcephaly, a severe congenital brain malformation that often leads to profound intellectual and developmental disabilities. Other maternal infections such as rubella and certain herpesviruses, particularly during the first trimester, are also known to harm the fetus directly, resulting in issues such as hearing loss, cerebral palsy, and autism. From the pandemic’s onset, Nielsen sensed that Covid, too, would leave its mark. “We saw this as a new pathogen and an opportunity to investigate its impact on these babies,” Nielsen says. She soon saw parallels. In 2021, the WHO confirmed that the coronavirus could cross the placental barrier via the maternal bloodstream, placing it in the same category as viruses like rubella and Zika. Some researchers believe the damage stems from inflammation triggered by the virus or viral components crossing the placenta. But Covid also appeared to affect fetuses in a unique way. One of the earliest signs emerged in early 2021 in County Cork, Ireland, during a surge of the alpha variant. A cluster of stillbirths in the first three months of that year prompted doctors to investigate. They discovered that the placentas linked to the fetal deaths were infected with the coronavirus, describing them as riddled with lesions likely caused by viral transmission through the maternal bloodstream. Similar cases began to surface in the US and at least 10 other countries, prompting David Schwartz, an Atlanta-based epidemiologist and perinatal pathologist, to lead an investigation. The findings were startling: on average, more than three-quarters of the tissue in infected placentas had been damaged, cutting off oxygen and nutrients essential for fetal survival. Alarmingly, this damage could occur silently, even in mothers without acute Covid symptoms, offering no warning signs. “We’ve never seen anything like this with an infectious disease,” said Schwartz, a medical anthropologist and pathologist with 45 years of experience studying placentas affected by pathogens such as HIV, Ebola, yellow fever, and Zika. “So far, I feel very confident in saying this is unique to this virus.” Studies by Schwartz and Nielsen highlighted that vaccination protects mothers against Covid’s obstetric complications, particularly during waves driven by variants more likely to cause severe disease. One possible clue to explaining the higher risks of neurodevelopmental issues seen in Nielsen’s study is that Covid, particularly in unvaccinated mothers, increases the risk of preterm delivery. In the US in 2021, the rate of preterm births rose by 4% to 10.5%, the highest since at least 2007. The likelihood of stillbirths nearly doubled for American mothers with Covid compared to those who avoided infection during the pandemic’s first year and a half. Similarly, a study in England found that mothers infected with SARS-CoV-2 at delivery were more than twice as likely to experience fetal death or preterm birth. Another explanation is that prolonged fevers triggered by illnesses like the flu can impair neural development indirectly by activating the maternal immune system. This creates an inflammatory environment in the uterus that can disrupt fetal brain development. Nielsen suspects that maternal immune activation might explain the high rates of neurodevelopmental delays observed among the infants in her study. Among at least four toddlers with severe delays, blood tests taken at birth revealed biomarkers of activated microglia – the brain’s immune cells – attacking neurons. “When you see microglial activation and neuronal signaling pathways traditionally associated with autism showing up in this cohort, it suggests there’s something behind it,” she says. Scientists say the full consequences of in utero exposure to the coronavirus may take decades to uncover and understand. Even if a link is established, genetics are likely to play a crucial role, according to Mady Hornig, a physician-scientist in New York. She is also an investigator on the Autism Birth Cohort project, a collaboration between the Norwegian Institute of Public Health and Columbia University studying the development of the condition for more than 20 years. Understanding the interplay of genetics with immune activity, inflammation, and stress might help unravel why some infants may face developmental challenges, she said. Identifying the various risks “requires additional rigorous study,” Hornig said. If Nielsen’s findings do reflect broader population trends the implications could be profound. “Early neurodevelopmental disturbances have potential implications for disability throughout a lifetime,” she said.Even small increases in risk could substantially add to the global burden of chronic disease, given the sheer number of pregnancies affected. Nielsen continues to analyze stored blood and other specimens from the babies in her study. “It’s a new pathogen. We don’t know how it behaves,” she said. “Things might appear down the road that we were not expecting.”
Stock market today: Wall Street hits records despite tariff talkBy Jason Gale | Bloomberg As COVID swept across California in early 2020, pediatric infectious diseases physician Karin Nielsen grew alarmed by the crisis erupting in maternity wards. Pregnant women were placed on life support, undergoing emergency C-sections as the virus triggered severe complications. Some died. Nielsen had just finished a research project on how the emerging infectious disease Zika was causing severe birth defects. Concerned the new coronavirus might have a similar impact, she began recruiting expectant mothers who tested positive for a new study. Soon after the study’s participants began giving birth, Nielsen’s colleagues at UCLA’s Mattel Children’s Hospital noticed an unusual number of their newborns requiring intensive care. Nielsen recalls another doctor stopping her to ask, “What’s wrong with the babies in your study?” NEXT PANDEMIC? How America lost control of the bird flu Sure enough, when researchers analyzed videos of the children lying on their backs in what’s called the General Movement Assessment, 14% of the infants showed signs of developmental problems. The test evaluates early motor functions and is often used to assess the risk of neurodevelopmental disorders including cerebral palsy. Later, during in-clinic assessments, the findings proved equally troubling. At 6-8 months old, 13 of 109 infants born to infected mothers — almost 12% — had failed to reach developmental milestones. In stark contrast, all infants in a control group born before the pandemic showed normal development. As additional participants from LA and Rio were enrolled, more unsettling results emerged. Around 11.6% of toddlers born to mothers with lab-confirmed SARS-CoV-2 infection during pregnancy showed cognitive, motor, or language problems indicative of neurodevelopmental delays. By comparison, only two of 128 unexposed controls — 1.6% — showed such issues. When the eldest of the Covid-exposed babies reached 28 months, the study found another concerning pattern: 23 of 211 children — almost 11% — screened positive for autism spectrum disorder. The finding, presented in May at a medical conference in Copenhagen, compared with an expected prevalence of 1-2% at that age, when some children begin showing signs of the condition. Around one in 36 or under 3% of children are eventually diagnosed with autism, according to the Centers for Disease Control and Prevention. “There’s something really going on,” Nielsen says. “We don’t want to alarm the world, but that’s what our data are showing.” The later findings, currently undergoing peer review ahead of publication, are a reminder that Covid’s long-term consequences, including higher risks for dementia and heart disease, continue to unravel almost five years after the pandemic began. While the virus is generally known to cause more severe symptoms in adults than in children, emerging research suggests that babies exposed to Covid in utero face elevated risks for preterm birth, congenital heart abnormalities and rare conditions, such as organs developing on the opposite side of the body. Greater odds of autism from in utero exposure to Covid would add another piece to the puzzle. The connection between the virus and autism remains inconclusive: some studies align with Nielsen’s findings, while others report little to no increased risk of developmental or behavioral issues. A limitation of Nielsen’s study is its relatively small sample size, with fewer than 250 mother-baby pairs. A robust understanding of the virus’ impact would likely require research involving more than 10,000 children, says Andrea Edlow, a maternal-fetal medicine specialist at Boston’s Massachusetts General Hospital. Such large-scale research has been difficult, particularly during the most deadly waves of the pandemic when clinic restrictions and medical emergencies obstructed consistent testing. Nielsen herself is wary of raising unnecessary fears. Autism remains something of a mystery, with its exact triggers still unclear. Scientists suspect an intersection of genetic and environmental factors, but the condition comes in many forms: some children have intellectual disabilities, while others don’t but still struggle with significant behavioral problems, complicating diagnoses. Many individuals with autism also experience co-occurring health issues such as attention-deficit/hyperactivity disorder, seizures, or chronic gastrointestinal problems. In much of the world, an awareness of autism is only starting to catch on. Global autism prevalence was estimated at 1 in 127 as of 2021 in a study published last week, more than double the 1-in-271 ratio reported in 2019, and researchers say this is likely driven by increased awareness and better diagnostic practices. The lack of clear explanations has provided fertile ground for myths, including the debunked belief that vaccines cause autism.Still, scientists say Nielsen’s study warrants serious attention due to the consistency of its findings. It also stands out for its rigor: trained physicians used standardized assessment tools at multiple points in time to evaluate developmental progress rather than relying on electronic health records or parent-completed questionnaires. Children born during the Covid era are now reaching the average age for autism diagnoses. Identifying developmental issues early can open the door to speech and behavioral therapies, which are proven to support a child’s development. This makes it a critical moment to study the pandemic’s impact. Nielsen, born to a Danish father and Brazilian mother in Rio de Janeiro, where she attended medical school, has dedicated much of her career to studying how maternal infections, such as HIV and Zika, affect child health. The mosquito-borne Zika virus is known for causing cerebral palsy and microcephaly, a severe congenital brain malformation that often leads to profound intellectual and developmental disabilities. Other maternal infections such as rubella and certain herpesviruses, particularly during the first trimester, are also known to harm the fetus directly, resulting in issues such as hearing loss, cerebral palsy, and autism. From the pandemic’s onset, Nielsen sensed that Covid, too, would leave its mark. “We saw this as a new pathogen and an opportunity to investigate its impact on these babies,” Nielsen says. She soon saw parallels. In 2021, the WHO confirmed that the coronavirus could cross the placental barrier via the maternal bloodstream, placing it in the same category as viruses like rubella and Zika. Some researchers believe the damage stems from inflammation triggered by the virus or viral components crossing the placenta. But Covid also appeared to affect fetuses in a unique way. One of the earliest signs emerged in early 2021 in County Cork, Ireland, during a surge of the alpha variant. A cluster of stillbirths in the first three months of that year prompted doctors to investigate. They discovered that the placentas linked to the fetal deaths were infected with the coronavirus, describing them as riddled with lesions likely caused by viral transmission through the maternal bloodstream. Similar cases began to surface in the US and at least 10 other countries, prompting David Schwartz, an Atlanta-based epidemiologist and perinatal pathologist, to lead an investigation. The findings were startling: on average, more than three-quarters of the tissue in infected placentas had been damaged, cutting off oxygen and nutrients essential for fetal survival. Alarmingly, this damage could occur silently, even in mothers without acute Covid symptoms, offering no warning signs. “We’ve never seen anything like this with an infectious disease,” said Schwartz, a medical anthropologist and pathologist with 45 years of experience studying placentas affected by pathogens such as HIV, Ebola, yellow fever, and Zika. “So far, I feel very confident in saying this is unique to this virus.” Studies by Schwartz and Nielsen highlighted that vaccination protects mothers against Covid’s obstetric complications, particularly during waves driven by variants more likely to cause severe disease. One possible clue to explaining the higher risks of neurodevelopmental issues seen in Nielsen’s study is that Covid, particularly in unvaccinated mothers, increases the risk of preterm delivery. In the US in 2021, the rate of preterm births rose by 4% to 10.5%, the highest since at least 2007. The likelihood of stillbirths nearly doubled for American mothers with Covid compared to those who avoided infection during the pandemic’s first year and a half. Similarly, a study in England found that mothers infected with SARS-CoV-2 at delivery were more than twice as likely to experience fetal death or preterm birth. Another explanation is that prolonged fevers triggered by illnesses like the flu can impair neural development indirectly by activating the maternal immune system. This creates an inflammatory environment in the uterus that can disrupt fetal brain development. Nielsen suspects that maternal immune activation might explain the high rates of neurodevelopmental delays observed among the infants in her study. Among at least four toddlers with severe delays, blood tests taken at birth revealed biomarkers of activated microglia – the brain’s immune cells – attacking neurons. “When you see microglial activation and neuronal signaling pathways traditionally associated with autism showing up in this cohort, it suggests there’s something behind it,” she says. Scientists say the full consequences of in utero exposure to the coronavirus may take decades to uncover and understand. Even if a link is established, genetics are likely to play a crucial role, according to Mady Hornig, a physician-scientist in New York. She is also an investigator on the Autism Birth Cohort project, a collaboration between the Norwegian Institute of Public Health and Columbia University studying the development of the condition for more than 20 years. Understanding the interplay of genetics with immune activity, inflammation, and stress might help unravel why some infants may face developmental challenges, she said. Identifying the various risks “requires additional rigorous study,” Hornig said. If Nielsen’s findings do reflect broader population trends the implications could be profound. “Early neurodevelopmental disturbances have potential implications for disability throughout a lifetime,” she said.Even small increases in risk could substantially add to the global burden of chronic disease, given the sheer number of pregnancies affected. Nielsen continues to analyze stored blood and other specimens from the babies in her study. “It’s a new pathogen. We don’t know how it behaves,” she said. “Things might appear down the road that we were not expecting.”Ange Postecoglou has revealed Tottenham are looking into why so many players have suffered injury setbacks this season. Ben Davies is the latest to fall into that category, with the Welsh international initially primed to return for Sunday’s visit of Wolves but no longer available. Davies suffered a setback in training this week, which means Spurs could be without a fit centre-back after Radu Dragusin was forced off in the latter stages of Thursday’s 1-0 loss at Nottingham Forest with an ankle issue. Ange with a team news update ahead of Wolves on Sunday 🗣️ — Tottenham Hotspur (@SpursOfficial) Postecoglou is already without first-choice central defenders Cristian Romero and Micky van de Ven after both failed to make it through their comeback fixture against Chelsea on December 7. “Yeah, that’s been our major problem this year. Guys who are coming back from injury rather than us losing players as such,” Postecoglou said. “We’re looking at those things and why they’re happening. It’s certainly happened too often this year where guys have come back and they’re the ones who are missing. “I think just about all of them, apart from Vic (Guglielmo Vicario), are recurrences of an injury. “Even with Romero, it was a different injury but it’s still a guy coming back, so it’s something we’re looking at.” There could be good news on the horizon with attackers Mikey Moore and Richarlison expected to return to training next week. Richarlison suffered his own setback in November when his short-lived return after a calf issue was cut short when he injured the same area against Aston Villa. Moore, meanwhile, has been sidelined by a virus for the best part of two months but the 17-year-old could provide a much-needed spark in the new year when Newcastle visit on January 4. Postecoglou said: “Him and Richy are in the final phases. Next week they can start training. We’ve got a bit of a gap before the Newcastle game. “The plan is Mikey and Richy come back into first-team training next week.” Anticipated returns for Moore and Richarlison will fail to help Postecoglou against Wolves, with makeshift centre-back Archie Gray potentially set to partner up with fellow midfielder Yves Bissouma if Dragusin cannot recover. Pressed on the issue of fixture scheduling, with Spurs definitely missing eight players for Sunday’s fixture, Postecoglou said: “It is challenging. “All clubs are going to have to get their heads around it and authorities are going to have to get their heads around it. “One of two things need to happen: either you somehow change the fixture schedule, which doesn’t seem feasible, or you allow clubs bigger squads. Then you have other issues with that, as well. “The attrition rate you’re seeing and it’s not just us. We’re going through a particularly badly moment. Newcastle went through it last year and it affected them pretty badly. They were obviously in the Champions League as well and probably didn’t have the squad to cope with it. “It hits certain clubs at different times and is probably becoming more prevalent, and for all of us it’s a challenge as to how we navigate this process to keep our players healthy. “It’s not just a physical thing, it’s a mental thing. For us it’s been constant since August and we’re not even halfway through the year. And they’re not going to get a break now, so these things we’re constantly assessing.”
Ange Postecoglou searching for answers over Tottenham’s injury crisisSTEVE FLOWERS: Alabama is one big front porch
Perry Minasian hoping groundwork was laid in Dallas for more Angels upgrades this winter
Stock market today: Wall Street hits records despite tariff talk
Reaction came too late, says City boss after 3-0 defeat to AltrinchamU.S. stocks closed at more records after Donald Trump’s latest talk about tariffs created only some ripples on Wall Street. The S&P 500 rose 0.6% to reach another all-time high. The Dow Jones Industrial Average added 0.3% to its own record set the day before, while the Nasdaq composite rose 0.6% as Big Tech stocks helped lead the way. Stock markets abroad saw mostly modest losses, after President-elect Trump said he plans to impose sweeping tariffs on Mexico, Canada and China as soon as he takes office. U.S. automakers and other companies that could be hurt particularly by such tariffs fell. On Tuesday: The S&P 500 rose 34.26 points, or 0.6%, to 6,021.63. The Dow Jones Industrial Average rose 123.74 points, or 0.3%, to 44,860.31. The Nasdaq composite rose 119.46 points, or 0.6%, to 19,174.30. The Russell 2000 index of smaller companies fell 17.72 points, or 0.7%, to 2,424.31. For the week: The S&P 500 is up 52.29 points, or 0.9%. The Dow is up 563.80 points, or 1.3%. The Nasdaq is up 170.65 points, or 0.9%. The Russell 2000 is up 17.64 points, or 0.7%. For the year: The S&P 500 is up 1,251.80 points, or 26.2%. The Dow is up 7,170.77 points, or 19%. The Nasdaq is up 4,162.95 points, or 27.7%. The Russell 2000 is up 397.23 points, or 19.6%.Google has unleashed another wave of artificial intelligence designed to tackle more of the work and thinking done by humans as it tries to stay on the technology's cutting edge. or signup to continue reading The next generation of Google's AI is being packaged under the Gemini umbrella, which was unveiled a year ago. Google is framing its release of Gemini 2.0 as a springboard for AI agents built to interpret images shown through a smartphone, perform a variety of tedious chores, remember the conversations consumers have with people, help video game players plot strategy and even tackle the task of doing online searches. In a blog post, Google CEO Sundar Pichai predicted the technology contained in Gemini 2.0 will "understand more about the world around you, think multiple steps ahead and take action on your behalf, with your supervision." A lot of Google's latest AI technology will initially be confined to test groups and subscribers who pay $US20 per month for Gemini Advanced, but some features will be made available through its search engine and mobile apps. Google is planning wider releases next year that will include the technology popping up in its smorgasbord of free products, including its Chrome browser, digital maps and YouTube. Besides trying to outshine OpenAI and other ambitious startups, Google is also trying to stay a step ahead of Apple as that trendsetting company begins to blend AI into its latest iPhones and other devices. After releasing a software update enabling the first bundle of the iPhone's Apple Intelligence features that spruced up the device's Siri assistant, another batch of the AI technology came out with a free software update that was also released on Wednesday. Google is pushing forward with its latest AI advances even as the US Justice Department is trying to break up the company to prevent further abusive practices by its dominant search engine, which was declared an illegal monopoly by a federal judge earlier this year as part of a landmark antitrust case. Among other things, Gemini 2.0 is supposed to improve the AI overviews that Google began highlighting in its search results over its traditional listing of the most pertinent links to websites earlier this year in response to AI-powered "answer engines" such as Perplexity. After the AI overviews initially produced some goofy suggestions, including putting glue on pizza, Google refined the technology to minimise such missteps. Now, company executives are promising things are going to get even better with Gemini 2.0, which Pichai said will be able to engage in more human-like reasoning while solving more advanced math problems and even churn out some computer code. The improvements to AI Overviews will initially only appear to a test audience before a wider release next year. As part of Gemini 2.0, Google is also going to begin testing an extension to Chrome called Project Mariner, which can be turned on to do online searches and sift through the results so people don't won't have to bother. If the US Department of Justice gets its way, Google will be forced to sell or spin off Chrome as part of its punishment for deploying its search engine in ways that stifled competition and potential innovation. Google has ridiculed the proposal as "overly broad" and vowed to resist any attempt to break up the company during federal court hearings scheduled to begin in Washington next year. DAILY Today's top stories curated by our news team. WEEKDAYS Grab a quick bite of today's latest news from around the region and the nation. WEEKLY The latest news, results & expert analysis. WEEKDAYS Catch up on the news of the day and unwind with great reading for your evening. WEEKLY Get the editor's insights: what's happening & why it matters. WEEKLY Love footy? We've got all the action covered. WEEKLY Every Saturday and Tuesday, explore destinations deals, tips & travel writing to transport you around the globe. WEEKLY Going out or staying in? Find out what's on. WEEKDAYS Sharp. Close to the ground. Digging deep. Your weekday morning newsletter on national affairs, politics and more. TWICE WEEKLY Your essential national news digest: all the big issues on Wednesday and great reading every Saturday. WEEKLY Get news, reviews and expert insights every Thursday from CarExpert, ACM's exclusive motoring partner. TWICE WEEKLY Get real, Australia! Let the ACM network's editors and journalists bring you news and views from all over. AS IT HAPPENS Be the first to know when news breaks. DAILY Your digital replica of Today's Paper. Ready to read from 5am! DAILY Test your skills with interactive crosswords, sudoku & trivia. Fresh daily! Advertisement Advertisement
WesBanco, Inc. and Premier Financial Corp. Announce Shareholder Approvals of Merger AgreementSan Francisco wins 85-64 over FordhamShares of communications platform Zoom Video Communications ( ZM -6.31% ) dropped on Tuesday after the technology company reported financial results for its fiscal third quarter of 2025. Everything in the quarter was actually fine. But going into the report, Zoom stock was at a two-year high and had risen over 50% in just a few months. It seems that financial results weren't quite inspiring enough to keep investors from taking recent profits off of the table. And that's why Zoom stock was down about 8% as of 2:45 p.m. ET. The beat and raise was modest for Zoom To reiterate, Zoom's financial results beat expectations on both the top and bottom lines. Moreover, management even raised its full-year guidance. Previously its guidance was for revenue of $4.630 billion to $4.640 billion, whereas now the revenue guidance is modestly higher at $4.656 billion to $4.661 billion. Similarly, Zoom's management expects full-year adjusted earnings per share (EPS) of $5.41 to $5.43, whereas before it only expected adjusted EPS of $5.29 to $5.31. Beating and raising guidance is good. But consider that Zoom's Q3 revenue was only up 3.6% year over year and guidance is only modestly higher. That's why investors weren't more upbeat about the report. One thing to watch One thing is for sure: Zoom is a profitable business with tons of cash. The company has $7.7 billion in cash, cash equivalents, and marketable securities. And it's on pace to generate about $1.6 billion in full-year free cash flow . With this, it's looking to give back to shareholders with a total buyback plan of about $2 billion as of this writing. The problem is that Zoom already repurchased 4.4 million shares in Q3 and yet the outstanding share count still went up due to stock-based compensation . Buyback plans boost the share price when the number of shares go down. So investors should keep an eye on stock-based compensation from here because it is one of the issues that's preventing Zoom stock from performing better.